Sharma A, Fierro M, Governor S, Kothare A, Pak S, Liu K
Cardiooncology. 2025; 11(1):23.
PMID: 40001253
PMC: 11852898.
DOI: 10.1186/s40959-025-00319-4.
Zhang X, Yin Y, Yu Q, Chen X, Cheng Y
Front Oncol. 2025; 14:1492203.
PMID: 39991185
PMC: 11842234.
DOI: 10.3389/fonc.2024.1492203.
Sabate-Tormos M, Bardaji A, Peiro O, Carrasquer A, Cediel G, Ferreiro J
Cardiooncology. 2025; 11(1):21.
PMID: 39987454
PMC: 11846249.
DOI: 10.1186/s40959-025-00320-x.
Tao K, Ye L, Xu Y, Yang M, Yin R, Li Q
Front Oncol. 2025; 15:1464368.
PMID: 39963113
PMC: 11830601.
DOI: 10.3389/fonc.2025.1464368.
Saeed H, Majeed U, Iqbal M, Shahid S, Hussain A, Iftikhar H
Int J Cardiol Cardiovasc Risk Prev. 2025; 24:200371.
PMID: 39925345
PMC: 11803891.
DOI: 10.1016/j.ijcrp.2025.200371.
Intrapericardial injection of hydrogels with ASC and their secretome to treat dilated cardiomyopathies.
Liguori T, Liguori G, Sinkunas V, Correia C, Dos Santos Coutinho E Silva R, Zanoni F
Sci Rep. 2025; 15(1):3529.
PMID: 39875493
PMC: 11775170.
DOI: 10.1038/s41598-025-87939-z.
Endothelin-based markers for endothelial dysfunction in chemotherapy-induced cardiotoxicity.
Boutin G, Yuzugulen J, Pranjol M
J Mol Cell Cardiol Plus. 2025; 6():100053.
PMID: 39802623
PMC: 11708141.
DOI: 10.1016/j.jmccpl.2023.100053.
New insights into mitochondrial quality control in anthracycline-induced cardiotoxicity: molecular mechanisms, therapeutic targets, and natural products.
Li W, Zhang Y, Wei Y, Ling G, Zhang Y, Li Y
Int J Biol Sci. 2025; 21(2):507-523.
PMID: 39781459
PMC: 11705644.
DOI: 10.7150/ijbs.103810.
Association of cardiovascular disease on cancer: observational and mendelian randomization analyses.
Bai T, Wu C
Sci Rep. 2024; 14(1):28465.
PMID: 39719456
PMC: 11668899.
DOI: 10.1038/s41598-024-78787-4.
High-Intensity Interval Training for Cancer Patients: A Review of Key Considerations for Exercise Prescription.
Dias-da-Silva Jr G, Panissa V, Derchain S, Ferreira M, Telles G, Buzaglo G
Sports Med. 2024; .
PMID: 39602033
DOI: 10.1007/s40279-024-02145-7.
The Descriptive and Disproportionality Assessment of EudraVigilance Database Reports on Capecitabine Induced Cardiotoxicity.
Vonica R, Butuca A, Vonica-Tincu A, Morgovan C, Pumnea M, Cipaian R
Cancers (Basel). 2024; 16(22).
PMID: 39594802
PMC: 11592987.
DOI: 10.3390/cancers16223847.
Cardiovascular Autonomic Dysfunction Before and After Chemotherapy in Cancer Patients.
Yoon S, Oh J
J Clin Neurol. 2024; 20(6):551-562.
PMID: 39505307
PMC: 11543394.
DOI: 10.3988/jcn.2024.0221.
Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease.
Jiang R, Lou L, Shi W, Chen Y, Fu Z, Liu S
Int J Mol Sci. 2024; 25(18).
PMID: 39337662
PMC: 11432657.
DOI: 10.3390/ijms251810177.
Evaluation of Left Atrial Electromechanical Delay and Left Atrial Phasic Functions in Patients Undergoing Treatment with Cardiotoxic Chemotherapeutic Agents.
Kertmen O, Akcay M
Medicina (Kaunas). 2024; 60(9).
PMID: 39336557
PMC: 11434181.
DOI: 10.3390/medicina60091516.
Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond.
Li X, Lin Y, Lin S, Huang J, Ruan Z
Front Pharmacol. 2024; 15:1404692.
PMID: 39211774
PMC: 11357958.
DOI: 10.3389/fphar.2024.1404692.
Associations of age at diagnosis of breast cancer with incident myocardial infarction and heart failure: A prospective cohort study.
Liang J, Pan Y, Zhang W, Gao D, Wang Y, Xie W
Elife. 2024; 13.
PMID: 39172036
PMC: 11341089.
DOI: 10.7554/eLife.95901.
Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study.
Provinciali N, Piccininno M, Siri G, Gennari A, Antonucci G, Ricci D
Rev Cardiovasc Med. 2024; 25(7):256.
PMID: 39139415
PMC: 11317344.
DOI: 10.31083/j.rcm2507256.
A case report of fludarabine associated ectopic atrial bradycardia and literature review of fludarabine induced bradycardia.
Kong S, Nagraj S, Cooper D, Ferrick K, Zhang L
Cardiooncology. 2024; 10(1):50.
PMID: 39123241
PMC: 11312176.
DOI: 10.1186/s40959-024-00253-x.
Risk factors for arrhythmias occurred in cancer patients after chemotherapy: An evidence-based systematic review and meta-analysis.
Xu Q, Han S, Wei X, You L, Sun L, Shang H
Heliyon. 2024; 10(14):e34176.
PMID: 39104480
PMC: 11298829.
DOI: 10.1016/j.heliyon.2024.e34176.
A fatal case of cabozantinib-induced cardiomyopathy.
Ibrahim S, Allihien S, Dadzie S, Atencah S, Akpan I
Future Cardiol. 2024; 20(10):537-541.
PMID: 39101435
PMC: 11485716.
DOI: 10.1080/14796678.2024.2383500.